Extensive adipocytic maturation can be seen in myxoid liposarcomas treated with neoadjuvant doxorubicin and ifosfamide and pre-operative radiation therapy

Clinical Sarcoma Research - Tập 2 Số 1 - 2012
Wei‐Lien Wang1, Daniela Katz2, Dejka M. Araujo3, Vinod Ravi3, Joseph A. Ludwig3, Jonathan C. Trent4, Shreyaskumar Patel3, Patrick P. Lin5, B. Ashleigh Guadagnolo6, Dolores López‐Terrada7, Angelo Paolo Dei Tos8, Valerie O Lewis5, Dina Lev9, Raphael E. Pollock10, Gunar K. Zagars6, Robert S. Benjamin3, John E. Madewell11, Alexander J. Lazar10
1Department of Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd Unit 085, Houston, TX, 77030, USA
2Sharette Institute of Oncology, Hadassah-Hebrew University Medical Center, POB 12000, Jerusalem, 91120, Israel
3Department of Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd Unit 085, Houston, TX, 77030, USA
4Sarcoma Multidisciplinary Program, The University Of Miami Sylvester Cancer Center, Room#C-050, 1475 Northwest 12th Avenue, Suite 3513, Miami, FL, 33136, USA
5Department of Othropeadic Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd Unit 085, Houston, TX, 77030, USA
6Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd Unit 085, Houston, TX, 77030, USA
7Department of Pathology, Texas Children's Hospital and Baylor College of Medicine, 6621 Fannin St, MC1-2261, Houston, TX, 77030, USA
8Department of Anatomic Pathology, General Hospital of Treviso, Piazza Ospedale 1, Treviso, 31100, Italy
9Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd Unit 085, Houston, TX, 77030, USA
10Sarcoma Research Center, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd Unit 085, Houston, TX, 77030, USA
11Department of MusculoSkeletal Radiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd Unit 085, Houston, TX, 77030, USA

Tóm tắt

Abstract Background Trabectedin and thioglitazones have been documented to induce adipocytic maturation in myxoid liposarcoma; we have noted this in our experience as well. Intriguingly, we have also encountered this same phenomenon in myxoid liposarcomas exposed to various combinations of neoadjuvant doxorubicin and ifosfamide systemic chemotherapy with preoperative radiation, where the pathological effects have been less characterized. We examined the histological changes, including adipocytic maturation, associated with this treatment in patients with myxoid liposarcoma and evaluated for prognostic significance. Methods Twenty-two patients were identified with histologically confirmed myxoid liposarcomas (9 with variable hypercellular areas) who were treated with neoadjuvant doxorubicin (75-90 mg/m2/continous infusion over 72h every 3 week) and ifosfamide (2.5 g/m2 daily x 4 every 3 weeks) for 4-6 cycles. Twenty-one patients received pre-operative radiation including 5 with concurrent gemcitabine. Pre- and post-treatment MRI studies were compared for changes in tumor area, fat content and contrast uptake, with the latter two estimated as: none, <25%, 25-49% and >50%. Post-treatment specimens were evaluated for hyalinization, necrosis and adipocytic maturation. Clinical follow-up was obtained. Results Median age was 45 (26-72) years with a median tumor size of 11 (2-18) cm. All occurred in the lower extremities except for one case in the neck. As is common in myxoid liposarcoma, all had extensive treatment changes (>90%) with extensive hyalinization (n = 16; >90%) or prominent adipocytic maturation (n = 6; >50%) including 2 cases composed almost entirely of mature-appearing adipose tissue. Variable necrosis was identified (5-30%). MRI revealed a decrease in tumor area in all but one tumor (median, 65%), an increase in fat content in 7 tumors (n = 2, >50%;n = 2, 25-50%;n = 3,<25%), and a decrease in contrast enhancement in most tumors (n = 5, >50%; n = 9, 25-49%; n = 7, <25%). Median follow-up was 57 (12-96) months with 17 alive with no disease/metastases, 3 alive with disease and 2 dead of disease. Six patients developed metastases with median interval of 26 (22-51) months post resection. Four of 6 tumors with increased adipocytic maturation >50% on histology had increased fat detected by MRI (>25%). All 6 are alive but 2 developed metastases. In the remaining patients, 4 developed metastases with 14 alive and 2 dead of disease. Conclusion Myxoid liposarcoma exposed to neoadjuvant doxorubicin and ifosfamide and pre-operative radiation can have prominent adipocytic maturation similar to trabectedin treatment. Myxoid liposarcomas exhibit extensive treatment changes with prominent hyalinization being the most common histological change. Despite this, patients develop metastases regardless of adipocytic maturation. While of unclear significance, no patient with fatty maturation died of disease.

Từ khóa


Tài liệu tham khảo

Evans HL: Liposarcoma: a study of 55 cases with a reassessment of its classification. Am J Surg Pathol. 1979, 3: 507-523. 10.1097/00000478-197912000-00004

Kilpatrick SE, Doyon J, Choong PF, Sim FH, Nascimento AG: The clinicopathologic spectrum of myxoid and round cell liposarcoma. A study of 95 cases. Cancer. 1996, 77: 1450-1458. 10.1002/(SICI)1097-0142(19960415)77:8<1450::AID-CNCR5>3.0.CO;2-G

Antonescu C, Ladanyi M: Myxoid Liposarcoma. Pathology and genetics of Tumuors of bone and soft tissue. Edited by: Fletcher CDM, Unni KK, Mertens F. 2002, Lyon: International Agency for Research on Cancer Press,

Weiss SW, Goldblum JR: Enzinger and Weiss’s soft tissue tumors. 2008, 498-510. Maryland Heights, MO: Mosby Elsevier, 5,

Haniball J, Sumathi VP, Kindblom LG: Prognostic factors and metastatic patterns in primary myxoid/round-cell liposarcoma. Sarcoma. 2011, 538085,

Antonescu CR, Tschernyavsky SJ, Decuseara R: Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. Clin Cancer Res. 2001, 7: 3977-3987.

Fritchie KJ, Goldblum JR, Tubbs RR: The expanded histologic spectrum of myxoid liposarcoma with an emphasis on newly described patterns: implications for diagnosis on small biopsy specimens. Am J Clin Pathol. 2012, 137: 229-239. 10.1309/AJCP90YNOKBAGCDM

Antonescu CR, Elahi A, Humphrey M: Specificity of TLS-CHOP rearrangement for classic myxoid/round cell liposarcoma: absence in predominantly myxoid well-differentiated liposarcomas. J Mol Diagn. 2000, 2: 132-138. 10.1016/S1525-1578(10)60628-9

Bode-Lesniewska B, Frigerio S, Exner U, Abdou MT, Moch H, Zimmermann DR: Relevance of translocation type in myxoid liposarcoma and identification of a novel EWSR1-DDIT3 fusion. Genes Chromosomes Cancer. 2007, 46: 961-971. 10.1002/gcc.20478

Crozat A, Aman P, Mandahl N, Ron D: Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature. 1993, 363: 640-644. 10.1038/363640a0

Hisaoka M, Tsuji S, Morimitsu Y: Detection of TLS/FUS-CHOP fusion transcripts in myxoid and round cell liposarcomas by nested reverse transcription-polymerase chain reaction using archival paraffin-embedded tissues. Diagn Mol Pathol. 1998, 7: 96-101. 10.1097/00019606-199804000-00006

Knight JC, Renwick PJ, Dal Cin P, Van den Berghe H, Fletcher CD: Translocation t(12;16)(q13;p11) in myxoid liposarcoma and round cell liposarcoma: molecular and cytogenetic analysis. Cancer Res. 1995, 55: 24-27.

Panagopoulos I, Mandahl N, Ron D: Characterization of the CHOP breakpoints and fusion transcripts in myxoid liposarcomas with the 12;16 translocation. Cancer Res. 1994, 54: 6500-6503.

Powers MP, Wang WL, Hernandez VS: Detection of myxoid liposarcoma-associated FUS-DDIT3 rearrangement variants including a newly identified breakpoint using an optimized RT-PCR assay. Mod Pathol. 2011, 23: 1307-1315.

Charytonowicz E, Terry M, Coakley K: PPARgamma agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma. J Clin Invest. 2012, 122: 886-898. 10.1172/JCI60015

Cheng H, Dodge J, Mehl E: Validation of immature adipogenic status and identification of prognostic biomarkers in myxoid liposarcoma using tissue microarrays. Hum Pathol. 2009, 40: 1244-1251. 10.1016/j.humpath.2009.01.011

Birch NC, Antonescu CR, Nelson M: Inconspicuous insertion 22;12 in myxoid/round cell liposarcoma accompanied by the secondary structural abnormality der(16)t(1;16). J Mol Diagn. 2003, 5: 191-194. 10.1016/S1525-1578(10)60472-2

Dal Cin P, Sciot R, Panagopoulos I: Additional evidence of a variant translocation t(12;22) with EWS/CHOP fusion in myxoid liposarcoma: clinicopathological features. J Pathol. 1997, 182: 437-441. 10.1002/(SICI)1096-9896(199708)182:4<437::AID-PATH882>3.0.CO;2-X

Hosaka T, Nakashima Y, Kusuzaki K: A novel type of EWS-CHOP fusion gene in two cases of myxoid liposarcoma. J Mol Diagn. 2002, 4: 164-171. 10.1016/S1525-1578(10)60698-8

Mrozek K, Szumigala J, Brooks JS, Crossland DM, Karakousis CP, Bloomfield CD: Round cell liposarcoma with the insertion (12;16)(q13;p11.2p13). Am J Clin Pathol. 1997, 108: 35-39.

Negri T, Virdis E, Brich S: Functional mapping of receptor tyrosine kinases in myxoid liposarcoma. Clin Cancer Res. 2010, 16: 3581-3593. 10.1158/1078-0432.CCR-09-2912

Demicco EG, Torres KE, Ghadimi MP: Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma. Mod Pathol. 2012, 25: 212-221.

Barretina J, Taylor BS, Banerji S: Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet. 2010, 42: 715-721. 10.1038/ng.619

Grosso F, Jones RL, Demetri GD: Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 2007, 8: 595-602. 10.1016/S1470-2045(07)70175-4

Casali PG, Sanfilippo R, D’Incalci M: Trabectedin therapy for sarcomas. Curr Opin Oncol. 2010, 22: 342-346. 10.1097/CCO.0b013e32833aaac1

Grohar PJ, Griffin LB, Yeung C: Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells. Neoplasia. 2011, 13: 145-153.

Grosso F, Sanfilippo R, Virdis E: Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann Oncol. 2009, 20: 1439-1444. 10.1093/annonc/mdp004

Demetri GD, Fletcher CD, Mueller E: Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A. 1999, 96: 3951-3956. 10.1073/pnas.96.7.3951

Roberge D, Skamene T, Nahal A, Turcotte RE, Powell T, Freeman C: Radiological and pathological response following pre-operative radiotherapy for soft-tissue sarcoma. Radiother Oncol. 2010, 97: 404-407. 10.1016/j.radonc.2010.10.007

Downs-Kelly E, Goldblum JR, Patel RM: The utility of fluorescence in situ hybridization (FISH) in the diagnosis of myxoid soft tissue neoplasms. Am J Surg Pathol. 2008, 32: 8-13. 10.1097/PAS.0b013e3181578d5a

Weaver J, Downs-Kelly E, Goldblum JR: Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms. Mod Pathol. 2008, 21: 943-949. 10.1038/modpathol.2008.84

Gronchi A, Bui BN, Bonvalot S: Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann Oncol. 2012, 23: 771-776. 10.1093/annonc/mdr265

Forni C, Minuzzo M, Virdis E: Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther. 2009, 8: 449-457. 10.1158/1535-7163.MCT-08-0848

Gerwirtz D: A Critical Evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol. 1999, 57: 727-741. 10.1016/S0006-2952(98)00307-4

Kerbusch T, de Kraker J, Keizer HJ: Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. Clin Pharmacakinet. 2001, 40: 41-62. 10.2165/00003088-200140010-00004.

Gamba-Vitalo C, Blair OC, Titton TR, Lane PA, Carbone R, Sartorelli AC: Cytotoxicity and differentiating actions of adriamycin in WEH1-3B D + leukemia cells. Leukemia. 1987, 1: 188-197.

Fornari FA, Jarvis WD, Grant S: Induction of differentiation and growth arrest associated with nascent (nonoliogsomal) DNA fragmentation and reduced c-myc expression in MCF-7 human breast tumor cells after continous exposure to a sublethal concentration of doxorubicin. Cell Growth & Differentiation. 1994, 5: 723-733.

Smith LM, Anderson JR, Coffin CM: Cytodifferentiation and clinical outcome after chemotherapy and radiation therapy for rhabdomyosarcoma (RMS). Med Pediatr Oncol. 2002, 38: 398-404. 10.1002/mpo.10060

Huang HY, Antonescu CR: Molecular variability of TLS-CHOP structure shows no significant impact on the level of adipogenesis: a comparative ultrastructural and RT-PCR analysis of 14 cases of myxoid/round cell liposarcomas. Ultrastruct Pathol. 2003, 27: 217-226. 10.1080/01913120309917

Thông tin
Thông tin xuất bản

Clinical Sarcoma Research

Tập 2 Số 1

Thông tin tác giả